Publications by authors named "Sylvia Zhao"

Claim this Profile
I
ICH M12 Drug Interaction Studies: Summary of the Efforts to Achieve Global Convergence.
Kellie Reynolds, Xinning Yang, Sheila Annie Peters, Vikram Sinha, Helen Heymann, Sylvia Zhao

Clin Pharmacol Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
Zhu Luo, Zhijun Huang, Feng Sun, Fang Guo, Yingying Wang, Sylvia Zhao

J Clin Lipidol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are you laughing with me or at me? Psychopathic traits and the ability to distinguish between affiliation and dominance laughter cues.
Rista C Plate, Sylvia Zhao, Chloe Katz, Edie Graber, Grace Daley

J Pers· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation.
Richard Zang, Aline Barth, Harvey Wong, Jan Marik, Jie Shen, Sylvia Zhao

J Med Chem· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Jean-Pierre Delord, Guillem Argilés, Jerôme Fayette, Lori Wirth, Stefan Kasper, Sylvia Zhao

Invest New Drugs· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Ulrike Glaenzel, Yi Jin, Regine Hansen, Kirsten Schroer, Gholamreza Rahmanzadeh, Sylvia Zhao

Drug Metab Dispos· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New paradigm for expediting drug development in Asia.
Iris Rajman, Masaru Hirano, Wataru Honma, Sylvia Zhao

Drug Discov Today· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
Yung-Jue Bang, Wu-Chou Su, Martin Schuler, Do-Hyun Nam, Wan Teck Lim, Sylvia Zhao

Cancer Sci· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
Martin van den Bent, Analia Azaro, Filip De Vos, Juan Sepulveda, W K Alfred Yung, Sylvia Zhao

J Neurooncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma.
Marc S Raab, Sheeba K Thomas, Enrique M Ocio, Andreas Guenther, Yeow-Tee Goh, Sylvia Zhao

Leukemia· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401.
Jiang Wei Zhang, Hai Bing Deng, Chun Ye Zhang, Jing Quan Dai, Qian Li, Sylvia Zhao

Eur J Drug Metab Pharmacokinet· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, Sylvia Zhao

J Clin Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytochrome P450 induction response in tethered spheroids as a three-dimensional human hepatocyte in vitro model.
Lei Xia, Xin Hong, Rashidah Binte Sakban, Yinghua Qu, Nisha Hari Singh, Sylvia Zhao

J Appl Toxicol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
Ke Li, Sylvia Zhao, Lingling Zhang, Xiaoyun Wu, Pan Shu

Drug Metab Dispos· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Sylvia Zhao

Cancer Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine.
Jagdish K Racha, Z Sylvia Zhao, Nicholas Olejnik, Nadine Warner, Rebecca Chan

Drug Metab Pharmacokinet· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis